RESPIRATORY TRACT INFECTION TREATMENT MARKET ANALYSIS

Respiratory Tract Infection Treatment Market, by Drug Class (Antibiotics, Non-Steroidal Anti-Inflammatory Drug (NSAIDS), Cough Suppressant, Nasal Decongestant, and Others), by Disease Indication (Upper Respiratory Tract Infection and Lower Respiratory Tract Infection), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, trends, and Forecast to 2026

Published In : Aug 2018
Code : CMI2030
Pages :157
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Respiratory Tract Infection Treatment Market- Competitive Landscape

Increasing approval of new drugs by the Food and Drug Administration (FDA) is also expected to propel the overall market growth over the forecast period. For instance, in November 2017, the U.S. FDA approved Fasenra (Benralizumab) manufactured by AstraZeneca, a respiratory biologic for patients aged 12 years and older who are suffering from asthma, and with an eosinophilic phenotype.

Key players operating in the global respiratory tract infection treatment market include Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd.

Respiratory Tract Infection Treatment Market Report Snapshots